One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2020-137572
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 10 |
Affiliation: The University of Texas MD Anderson Cancer Center, Princess Margaret Cancer Centre, City Of Hope National Medical Center, University of Kansas Cancer Center, Roswell Park Cancer Institute, Presbyterian Hospital, New York Hospital Queens, NewYork–Presbyterian Hospital, Cornell University, Ronald Reagan UCLA Medical Center, Ark Therapeutic (United States), Mayo Clinic, Michigan Medicine, Alberta Hospital Edmonton, Tufts Medical CenterA Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
